Dr. Mahal on the Emerging Role of Epigenomics in Prostate Cancer

Video

In Partnership With:

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the emerging role of epigenomics in prostate cancer.

Ongoing research in the field of epigenomics has garnered significant attention in prostate cancer, says Mahal.

Developing a greater understanding of the molecular characteristics of prostate cancer may lend insight into drivers of prostate cancer and disease aggressiveness, Mahal explains.

Moreover, epigenetics may inform the influence the environment has on a patient’s genome and on disparities between patient subgroups with prostate cancer, concludes Mahal.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD